Hepatic FMO3 Downregulation Contributes to the Metabolic Benefits of Vertical Sleeve Gastrectomy
Obesity · 2026
DOI: 10.1002/oby.70281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, 2026. Verfasst von Hai Yan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Obesity and Hernia Surgery, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Liver, Gastrectomy, Oxygenases, Obesity. Die Arbeit nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
Metabolic bariatric surgery, such as vertical sleeve gastrectomy (VSG), is the most effective treatment for obesity, yet the molecular mechanisms remain incompletely defined. This study aims to explore the role of hepatic flavin monooxygenase 3 (FMO3) in the metabolic improvements of VSG.
Methods
Hepatic FMO3 was assessed in liver biopsies from human patients. Diet‐induced obese mice underwent VSG, targeted hepatic FMO3 inhibition with antisense oligonucleotides, or VSG with concurrent FMO3 knockdown. Outcomes included weight loss, glucose tolerance, insulin sensitivity, serum lipids, hepatic steatosis, circulating bile acid profiling, hepatic gene expression involved in the FXR pathway, and bile acid synthesis/transport.
Results
In mouse models, VSG suppressed hepatic FMO3 expression, leading to significant weight loss, enhanced glucose and lipid metabolism, and reduced hepatic steatosis. Inhibition of FMO3 using antisense oligonucleotides recapitulated many of these effects, while silencing FMO3 diminished VSG's metabolic benefits. Clinical data revealed elevated hepatic FMO3 expression in patients with obesity and its downregulation after VSG, correlating with metabolic improvements. Additionally, FMO3 downregulation was associated with alterations in bile acid metabolism and FXR signaling.
Conclusions
Hepatic FMO3 downregulation contributes importantly to the metabolic benefits of VSG. Targeting hepatic FMO3 may offer a nonsurgical strategy to reproduce key clinical benefits of metabolic bariatric surgery. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Obesity and Hernia Surgery, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
- Department of General Surgery, Shanghai International Medical Center, Shanghai, China.
- Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Yuxiao Chu, Qiyuan Yao, Yikai Shao
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yan, H., Cao, C., Tan, X., Huang, X., Liu, Y., Chu, Y., He, M., Yao, Q., Hua, R., & Shao, Y. (2026). Hepatic FMO3 Downregulation Contributes to the Metabolic Benefits of Vertical Sleeve Gastrectomy. Obesity. https://doi.org/10.1002/oby.70281
Vancouver
Yan H, Cao C, Tan X, Huang X, Liu Y, Chu Y, et al. Hepatic FMO3 Downregulation Contributes to the Metabolic Benefits of Vertical Sleeve Gastrectomy. Obesity. 2026. doi:10.1002/oby.70281
BibTeX
@article{Yan2026,
author = {Yan, Hai and Cao, Chong and Tan, Xiaozhuo and Huang, Xianjue and Liu, Yanyang and Chu, Yuxiao and He, Mengcheng and Yao, Qiyuan and Hua, Rong and Shao, Yikai},
title = {Hepatic FMO3 Downregulation Contributes to the Metabolic Benefits of Vertical Sleeve Gastrectomy},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70281}
}
EUVIMED